+

WO2003015692A3 - Domaine de fixation aux ligands du recepteur du glucocorticoide cristallise et procedes de criblage l'utilisant - Google Patents

Domaine de fixation aux ligands du recepteur du glucocorticoide cristallise et procedes de criblage l'utilisant Download PDF

Info

Publication number
WO2003015692A3
WO2003015692A3 PCT/US2002/022648 US0222648W WO03015692A3 WO 2003015692 A3 WO2003015692 A3 WO 2003015692A3 US 0222648 W US0222648 W US 0222648W WO 03015692 A3 WO03015692 A3 WO 03015692A3
Authority
WO
WIPO (PCT)
Prior art keywords
test
polypeptide
crystallized
binding domain
ligand binding
Prior art date
Application number
PCT/US2002/022648
Other languages
English (en)
Other versions
WO2003015692A2 (fr
Inventor
Christopher J Apolito
Randy K Bledsoe
Millard H Lambert Iii
David D Mckee
Valerie Gail Montana
Kenneth H Pearce
Thomas B Stanley
Huaqiang Eric Xu
Christopher J Delves
Original Assignee
Smithkline Beecham Corp
Christopher J Apolito
Randy K Bledsoe
Millard H Lambert Iii
David D Mckee
Valerie Gail Montana
Kenneth H Pearce
Thomas B Stanley
Huaqiang Eric Xu
Christopher J Delves
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Christopher J Apolito, Randy K Bledsoe, Millard H Lambert Iii, David D Mckee, Valerie Gail Montana, Kenneth H Pearce, Thomas B Stanley, Huaqiang Eric Xu, Christopher J Delves filed Critical Smithkline Beecham Corp
Priority to US10/484,061 priority Critical patent/US7238778B2/en
Priority to AU2002355929A priority patent/AU2002355929A1/en
Publication of WO2003015692A2 publication Critical patent/WO2003015692A2/fr
Publication of WO2003015692A3 publication Critical patent/WO2003015692A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Theoretical Computer Science (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)

Abstract

L'invention porte sur un procédé de modification d'un récepteur nucléaire d'essais (RNE) pouvant consister: à sélectionner une séquence de RNE présentant une caractéristique ciblée en vue de sa modification; à aligner ladite séquence de RNE avec au moins une séquence de récepteur nucléaire de référence (RNR) pour laquelle une structure obtenue par rayons X est disponible, et présentant une caractéristique souhaitée du RNE; à construire un modèle en 3D du RNE à l'aide des coordonnées en 3D de la structure obtenue par rayons X du RNR, et de l'alignement de ses séquences avec celle du RNE; à examiner le modèle en 3D du RNE pour y déceler les différences avec le RNR associés à la caractéristique souhaitée; à muter l'un au moins un résidu d'acides nucléiques de la séquence du RNE située au niveau d'une différence identifiée au-dessus d'un résidu associé à la caractéristique souhaitée, de manière à créer une modification du RNE. L'invention porte également: sur un récepteur de glucocorticoïdes (RG) isolé présentant une mutation d'un domaine de fixation de ligands modifiant la solubilité dudit domaine; sur un RG isolé ou ses parties fonctionnelles présentant une ou plusieurs mutations consistant à substituer un résidu d'acide nucléique hydrophobe à un résidu d'acide nucléique hydrophile, les mutations représentatives étant les substitutions F602S et F602D; sur l'expression du RG dans le E.coli; sur la structure cristalline en 3D résolue du domaine de fixation aux ligands du RGα ainsi que sur la forme cristalline dudit domaine; et sur des procédés d'élaboration de modulateurs de l'activité biologique du RGα et d'autres récepteurs nucléaires, récepteurs stéroïdiens, et récepteurs de glucocorticoïdes, et de leur domaine de fixation aux ligands.
PCT/US2002/022648 2001-07-17 2002-07-17 Domaine de fixation aux ligands du recepteur du glucocorticoide cristallise et procedes de criblage l'utilisant WO2003015692A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/484,061 US7238778B2 (en) 2001-07-17 2002-07-17 Crystallized glucocorticoid receptor ligand binding domain polypeptide and screening methods employing same
AU2002355929A AU2002355929A1 (en) 2001-07-17 2002-07-17 Crystallized glucocorticoid receptor ligand binding domain polypeptide and screening methods employing same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30590201P 2001-07-17 2001-07-17
US60/305,902 2001-07-17

Publications (2)

Publication Number Publication Date
WO2003015692A2 WO2003015692A2 (fr) 2003-02-27
WO2003015692A3 true WO2003015692A3 (fr) 2003-10-02

Family

ID=23182861

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/022648 WO2003015692A2 (fr) 2001-07-17 2002-07-17 Domaine de fixation aux ligands du recepteur du glucocorticoide cristallise et procedes de criblage l'utilisant

Country Status (3)

Country Link
US (1) US7238778B2 (fr)
AU (1) AU2002355929A1 (fr)
WO (1) WO2003015692A2 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6434489B1 (en) * 2000-04-03 2002-08-13 Schering Corporation Compositions of hepatitis C virus NS5B polymerase and methods for crystallizing same
GB0209507D0 (en) * 2002-04-25 2002-06-05 Karobio Ab Nuclear receptor structure
EP1375517A1 (fr) * 2002-06-21 2004-01-02 Smithkline Beecham Corporation Structure du domaine de liaison du ligand du récepteur de glucocorticoides comportant une poche de liaison expansée et procédé d'emploi
US7442554B2 (en) 2002-07-18 2008-10-28 Bristol-Myers Squibb Company Compositions and methods involving glucocorticoid receptor site II
JP2006265173A (ja) * 2005-03-24 2006-10-05 Sumitomo Chemical Co Ltd グルココルチコイド受容体リガンド結合ドメインとリガンドとの複合体を含む結晶
WO2006117592A1 (fr) * 2005-04-29 2006-11-09 Inserm Procedes de modulation de recepteurs nucleaires
JP2007008897A (ja) * 2005-07-04 2007-01-18 Sumitomo Chemical Co Ltd グルココルチコイド受容体リガンド結合ドメインとリガンドとの複合体を含む結晶
US7910565B2 (en) 2006-09-01 2011-03-22 Wisconsin Alumni Research Foundation Prostate cancer vaccine
WO2010101565A1 (fr) * 2009-03-04 2010-09-10 Shriners Hospitals For Children Allèles de récepteurs des glucocorticoïdes et leurs utilisations
US20120095055A1 (en) * 2009-06-02 2012-04-19 Merck Sharp & Dohme, Corp. HEXAHYDROCYCLOPENTYL[f]INDAZOLE 5-HYDROXYMETHYL ETHANOLS AND DERIVATIVES THEREOF AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS
US20120172397A1 (en) * 2009-09-08 2012-07-05 Merck Sharp & Dohme Corp. HEXAHYDROCYCLOPENTA[f]INDAZOLE 5-YL ETHANOLS AND DERIVATIVES THEREOF AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS
CN103080108A (zh) * 2010-08-27 2013-05-01 科赛普特治疗公司 吡啶基-胺稠合的氮杂萘烷调节剂
US9189594B2 (en) 2010-08-31 2015-11-17 Annai Systems Inc. Method and systems for processing polymeric sequence data and related information
CN103298343A (zh) 2011-01-07 2013-09-11 科赛普特治疗公司 类固醇和糖皮质激素受体拮抗剂组合疗法
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US12226412B2 (en) 2012-05-25 2025-02-18 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
AU2013277986B2 (en) 2012-06-22 2016-12-01 Annai Systems Inc. System and method for secure, high-speed transfer of very large files
DK3848027T3 (da) 2013-11-25 2023-05-01 Corcept Therapeutics Inc Octahydro-kondenserede azadecalinglucocorticoidreceptormodulatorer
CN110520121B (zh) 2017-03-31 2023-07-04 科赛普特治疗学股份有限公司 糖皮质激素受体调节剂治疗宫颈癌
EP3897589A4 (fr) 2018-12-19 2022-10-12 Corcept Therapeutics Incorporated Formulations pharmaceutiques contenant un rélacorilant, un composé azadécaline fusionné avec une hétéroarylcétone
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
WO2020132046A1 (fr) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Méthodes de traitement du cancer comprenant l'administration d'un modulateur du récepteur des glucocorticoïdes et d'un agent chimiothérapeutique anticancéreux
SG11202108964YA (en) 2019-02-22 2021-09-29 Corcept Therapeutics Inc Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
JP7569492B2 (ja) 2019-12-11 2024-10-18 コーセプト セラピューティクス， インコーポレイテッド 抗精神病薬誘発性体重増加のミリコリラントによる治療方法
CN112695052A (zh) * 2020-12-25 2021-04-23 华南农业大学 一种重组人糖皮质激素受体GRα-His蛋白及其表达和纯化方法
WO2022134033A1 (fr) 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Procédés de préparation de modulateurs du récepteur des glucocorticoïdes d'azadécaline fusionnée hétéroaryle-cétone
CN112553231A (zh) * 2020-12-25 2021-03-26 华南农业大学 一种重组人热休克蛋白HSP90-His及其表达和纯化方法
CN119790079A (zh) * 2022-06-27 2025-04-08 上海奕拓医药科技有限责任公司 用于调节分子的组合物和方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000052050A2 (fr) * 1999-03-01 2000-09-08 Karo Bio Ab Modeles d'homologie du recepteur de glucocorticoide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532167A (en) * 1994-01-07 1996-07-02 Beth Israel Hospital Substrate specificity of protein kinases
FR2745008A1 (fr) * 1996-02-20 1997-08-22 Ass Pour Le Dev De La Rech En Recepteur nucleaire de glucocorticoides modifie, fragments d'adn codant pour ledit recepteur et procedes dans lesquels ils sont mis en oeuvre

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000052050A2 (fr) * 1999-03-01 2000-09-08 Karo Bio Ab Modeles d'homologie du recepteur de glucocorticoide

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BLEDSOE ET AL.: "Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition", CELL, vol. 110, 12 July 2002 (2002-07-12), pages 93 - 105, XP002964887 *
DEY ET AL.: "Homology modelling of the ligand-binding domain of glucocorticoid receptor: binding site interactions with cortisol and corticosterone", PROTEIN ENGINEERING, vol. 14, no. 8, 2001, pages 565 - 571, XP002964886 *
JAGERSCHMIDT ET AL.: "Residues in the ligand binding domain that confer progestin or glucocorticoid specificity and modulate the receptor transactivation capacity", MOLECULAR ENDOCRINOLOGY, vol. 14, no. 7, 2000, pages 1028 - 1037, XP002964885 *

Also Published As

Publication number Publication date
AU2002355929A1 (en) 2003-03-03
US20050181362A1 (en) 2005-08-18
US7238778B2 (en) 2007-07-03
WO2003015692A2 (fr) 2003-02-27

Similar Documents

Publication Publication Date Title
WO2003015692A3 (fr) Domaine de fixation aux ligands du recepteur du glucocorticoide cristallise et procedes de criblage l'utilisant
GB2391358B (en) System on chip (soc) and method of testing and/or debugging the system on chip
AU2003224959A1 (en) Method and apparatus for secure scan testing
AU9104798A (en) Methods for selecting, developing and improving diagnostic tests for pregnancy-related conditions
AU2002341621A1 (en) Methods, reagents, kits and apparatus for protein function analysis
IL156618A0 (en) Crystals of whole antibodies and fragments thereof, methods for the preparation thereof and diagnostic kits utilizing the same
AU2002317618A1 (en) System and method for automated analysis of load testing results
WO2004014311A3 (fr) Antagonistes de recepteur nogo
WO2001085790A3 (fr) Proteines de recepteur de mammifere, reactifs lies et techniques
AU2001274920A1 (en) Mammalian receptor proteins; related reagents and methods
AU2003272829A1 (en) System and method for defect localization on electrical test structures
AU3188999A (en) Development of human monoclonal antibodies and uses thereof
WO2004068115A3 (fr) Procede relatif a des essais de reactions a transfert de groupe
EP1433792A8 (fr) Protéines réceptrices humaines, réactifs et méthodes associés
AU2661199A (en) Mammalian receptor proteins; related reagents and methods
WO2002068646A3 (fr) Cytokines de mammiferes; recepteurs; reactifs et procedes correspondants
WO2003045975A3 (fr) Immobilisation en phase solide de proteines et de peptides
AU2001225804A1 (en) Improved test structures and methods for inspecting and utilizing the same
AU1919201A (en) Mammalian receptor proteins; related reagents and methods
AU2002361075A1 (en) Test result analysis apparatus, method, and program, and learning support system and method
EP1029916A4 (fr) Recepteur d'acide lysophosphatidique humain et utilisation dudit recepteur
EP0882985A3 (fr) Détermination immunochimiques des analytes multivalents
AU2002331712A1 (en) Bioequivalence test for iron-containing formulations
WO2002093297A3 (fr) Procede et systeme de planification, d'execution et d'evaluation du criblage haut rendement de compositions chimiques a composants multiples et de formes solides de composants
WO2005049652A3 (fr) Procede de generation in vitro d'une diversite d'anticorps

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10484061

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载